# US 2025/0152533 A1 · Novel Beta-Alanine Compositions and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152533 A1
- Document ID: US20250152533A1
- Status: Published application
- Kind: A1
- Application number: 18/916,596
- Filed: 2024-10-15
- Published: 2025-05-15
- Earliest claimed: 2023-11-14
- Assignees: Natural Alternatives International, Inc.
- Applicants: Natural Alternatives International, Inc.
- Inventors: Sreeraj Gopi; Di Tan
- Web page: https://patentgrep.com/patent/US20250152533A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/015: carbocyclic
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are novel beta-alanine compositions for increasing athletic performance, improving cognitive function, and attenuating the aging process. Compositions described herein can be administered to subjects, such as elderly subject, in functional or medical foods, along with other formulations to aid in healthy aging including reduced muscle wasting, improved mobility, improved cognitive performance, and the like. The compositions described herein comprise improved bioavailability and reduced paresthesia effects compared to free beta-alanine. Also described herein are methods of making the novel beta-alanine compositions disclosed herein.

## Claims

### Claim 1

A composition comprising:
at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
an anti-inflammatory agent;
an amphiphilic agent; and
a stimulant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition comprises:
at least about 1 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
at most about 99 wt. % of the anti-inflammatory agent,
at most about 99 wt. % of the amphiphilic agent, and
at most about 99 wt. % of the stimulant.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the composition comprises:
between about 10 wt. % and about 99 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
between about 0.01 wt. % and about 50 wt. % of the anti-inflammatory agent;
between about 0.01 wt. % and about 50 wt. % of the amphiphilic agent; and
between about 0.01 wt. % and about 50 wt. % of the stimulant.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the composition comprises:
between about 50 wt. % and about 80 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
between about 0.01 wt. % and about 10 wt % of the anti-inflammatory agent;
between about 0.1 wt. % and about 10 wt. % of the amphiphilic agent; and
between about 0.01 wt. % and about 10 wt. % of the stimulant.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the composition comprises:
between about 70 wt. % and about 80 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
between about 0.1 wt. % and about 4 wt. % of the anti-inflammatory agent;
between about 1 wt. % and about 10 wt. % of the amphiphilic agent; and
between about 0.1 wt. % and about 1 wt. % of the stimulant.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the anti-inflammatory agent is beta-caryophyllene.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the stimulant is caffeine.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the amphiphilic agent is a phospholipid.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the phospholipid is lecithin.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition is coated with a coating agent.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the coating agent is a modified food starch.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the composition is formulated as a pharmaceutical composition or a dietary supplement.

### Claim 13 (depends on 5)

The composition of claim 5, wherein the composition comprises:
between about 70 wt. % and about 73 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
between about 0.5 wt. % and about 1 wt. % of the anti-inflammatory agent;
between about 1 wt. % and about 5 wt. % of the amphiphilic agent; and
between about 0.1 wt. % and about 0.2 wt. % of the stimulant.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition is formulated as a human dietary supplement.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine is provided in an amount ranging from about 0.02 g to about 10 g per serving.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine is provided in an amount ranging from about 0.03 g to about 6.4 g per serving.

### Claim 17 (depends on 14)

The composition of claim 14, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine is provided in an amount ranging from about 0.04 g to about 3.2 g per serving.

### Claim 18 (depends on 14)

The composition of claim 14, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine is provided in an amount ranging from about 0.05 g to about 2.24 g per serving.

### Claim 19 (depends on 14)

The composition of claim 14, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine is provided in an amount ranging from about 0.1 g to about 1 g per serving.

### Claim 20 (depends on 14)

The composition of claim 14, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine is provided in an amount ranging from about 0.2 g to about 0.8 g per serving.

### Claim 21

A method for increasing athletic performance and/or improving cognitive function without causing paresthesia in a subject, the method comprising:
administering an effective amount of a composition to the subject, wherein the composition comprises:
at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine; and
at least one agent selected from the group consisting of an anti-inflammatory agent and an amphiphilic agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine in the composition is provided in an amount ranging from 0.02 g to about 10 g per day.

### Claim 23 (depends on 21)

The method of claim 21, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine in the composition is provided in an amount ranging from about 0.05 g to about 2.24 g per day.

### Claim 24 (depends on 21)

The method of claim 21, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine in the composition is provided in an amount ranging from about 0.1 g to about 1 g per day.

### Claim 25 (depends on 21)

The method of claim 21, wherein the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine in the composition is provided in an amount ranging from about 0.2 g to about 0.8 g per day.

### Claim 26 (depends on 21)

The method of claim 21, wherein the composition further comprises a stimulant.

### Claim 27 (depends on 26)

The method of claim 26, wherein the composition comprises:
at least about 1 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
at most about 99 wt. % of the anti-inflammatory agent;
at most about 99 wt. % of the amphiphilic agent; and
at most about 99 wt. % of the stimulant.

### Claim 28 (depends on 27)

The method of claim 27, wherein the composition comprises:
between about 10 wt. % and about 99 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
between about 0.01 wt. % and about 50 wt. % of the anti-inflammatory agent;
between about 0.01 wt. % and about 50 wt. % of the amphiphilic agent; and
between about 0.01 wt. % and about 50 wt. % of the stimulant.

### Claim 29 (depends on 28)

The method of claim 28, wherein the composition comprises:
between about 50 wt. % and about 80 wt. % of the at least one compound selected from the group consisting of beta-alanine, an ester of beta-alanine, and a salt of beta-alanine;
between about 0.01 wt. % and about 10 wt. % of the anti-inflammatory agent;
between about 0.1 wt. % and about 10 wt. % of the amphiphilic agent; and
between about 0.01 wt. % and about 10 wt. % of the stimulant.

### Claim 30

A method of making a beta-alanine composition, the method comprising:
step (a) adding an amphiphilic agent to water to form a first solution;
step (b) homogenizing the first solution to form a first emulsion;
step (c) adding an anti-inflammatory agent to the first emulsion to form a second solution;
step (d) homogenizing the second solution to form a second emulsion;
step (e) adding beta-alanine, a salt of beta-alanine, and/or an ester of beta-alanine into the second emulsion to form a third solution; and
step (f) homogenizing the third solution to form a third emulsion.
